Chugai Pharmaceutical Co., Ltd.

Stocks

4519

JP3519400000

Market Closed - Japan Exchange Other stock markets 04:30:00 11/06/26 pm AEST			5-day change	1st Jan Change
7,428.00 ^JPY	-1.75%		+0.07%	-9.89%

26/05	Major Asian Stock Markets Fall Amid Renewed Middle East Tensions	MT
11/05	Jefferies Adjusts Chugai Pharmaceutical's Price Target to 8,500 Yen from 9,100 Yen, Keeps at Hold	MT

Transcript : Chugai Pharmaceutical Co., Ltd., Q1 2026 Earnings Call, Apr 24, 2026

Published on 04/24/2026 at 09:05 pm AEST - Modified on 04/25/2026 at 12:05 am AEST

S&P Capital IQ

Presenter Speech
????? (Executives)

Thank you very much for taking time out of your very busy schedules to attend our first quarter FY 2026 earnings call. My name is Miyata from Corporate Communication

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Chugai Pharmaceutical Co., Ltd.

26/05	Major Asian Stock Markets Fall Amid Renewed Middle East Tensions	MT
11/05	Jefferies Adjusts Chugai Pharmaceutical's Price Target to 8,500 Yen from 9,100 Yen, Keeps at Hold	MT
07/05	Japan's Nikkei blazes past 63,000 on earnings, Iran peace optimism; JGBs rally	RE
07/05	Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism	RE
28/04	Protara Therapeutics, Inc. to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting	CI
27/04	Earnings Season, Tehran Proposal Lift Asian Stock Markets	MT
27/04	Japan's Nikkei closes above 60,000 for first time on earnings optimism	RE
27/04	Keyence, Fanuc Shares Climb, Chugai Declines as Japan Stocks Mixed After Earnings	MT
27/04	Japan's Nikkei hits record high on earnings, Middle East optimism	RE
24/04	Chugai Pharmaceutical Co., Ltd., Q1 2026 Earnings Call, Apr 24, 2026
24/04	Chugai Pharmaceutical's Q1 Income Rises 19%	MT
24/04	Chugai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk	CI
10/04	Foundayo? (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S	CI
06/04	Jefferies Adjusts Chugai Pharmaceutical's Price Target to 9,100 Yen from 7,500 Yen, Keeps at Hold	MT